Federal University of Sao Paulo   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Sao Paulo Brazil (1933)

Organization Overview

First Clinical Trial
2002
NCT01267370
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Centro Mente Aberta de Mindfulness | Clarice Blaj Neufeld | Daniela Francescato Veiga | Division of Rheumatology, Federal University of Sao Paulo | Escola Paulista de Medicina Universidade Federal de São Paulo | Federal University of Sao Paulo | Federal University of São Paulo | Federal University of Sao Paulp | JULIANA AQUINO DE MOURA | Marcelo Demarzo, MD, PhD | Mauro Batista de Morais | Rubens Belfort Jr. | Sao Paulo Federal University | Soraia Tahan | Universidade Federal de São Paulo | Vanessa Marques Ferreira

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Back Pain (Phase 3)

Calcinosis (Phase 3)

Constipation (Phase 4)

Dry Eye Syndromes (Phase 3)

Edema (Phase 4)

Keratoconjunctivitis Sicca (Phase 3)

Low Back Pain (Phase 3)

Lupus Erythematosus, Systemic (Phase 3)

Macular Edema (Phase 4)

Scleroderma, Diffuse (Phase 4)

Scleroderma, Systemic (Phase 4)

Sclerosis (Phase 4)

Sjogren's Syndrome (Phase 3)

Vascular Calcification (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 40
  • # of Trial APIs: 42